OCUGEN INC (OCGN)
Health Care · Gene therapy / inherited retinal disease treatment · NASDAQ
A gene therapy company developing novel modifier gene therapies to treat inherited retinal diseases, including retinitis pigmentosa, Stargardt disease, and geographic atrophy.
What OCUGEN INC does
Ocugen is a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases and blindness. The company's core platform is a novel modifier gene therapy approach using nuclear hormone receptors (NHRs) to address genetic blindness diseases with a gene-agnostic strategy. Its lead programs include OCU400 for retinitis pigmentosa (RP), OCU410ST for Stargardt disease, and OCU410 for geographic atrophy, with multiple late-stage trials underway and BLA submissions planned through 2027.
Themes: ["Gene therapy / inherited retinal diseases","Retinitis pigmentosa (RP) treatment","Stargardt disease / ABCA4-associated retinopathies","Geographic atrophy / age-related macular degeneration (AMD)","Rare genetic blindness diseases","Advanced Therapy Medicinal Product (ATMP)"]
Fundamentals
- Price$1.47 as of 2026-07-09 close
- Market cap$491M as of 2026-07-10
- 1-year return+30.1% as of 2026-07-09 close
- Net margin-1158.6% as of 2026-07-10
- ROE-1306.7% as of 2026-07-10
- Debt / equity5.03 as of 2026-07-10
- Revenue growth (YoY)+3.0% as of 2026-07-10
- Revenue CAGR (3y)+21.0% SEC XBRL
- Beta2.16 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: regulatory approval of OCU400, OCU410ST, and OCU410 is uncertain; the company must successfully complete Phase 3 trials and obtain FDA/EMA approval, with topline Phase 3 data for OCU400 not expected until Q1 2027.","Funding risk: as an unprofitable, clinical-stage company with negative net margins of -1158.59%, Ocugen requires continuous additional financing to fund ongoing development programs and operations; failure to secure adequate capital could delay or halt programs.","Market adoption and reimbursement risk: even if OCU400, OCU410ST, and OCU410 are approved, there is no guarantee of market acceptance, adequate pricing, reimbursement coverage, or commercial success in competing markets for inherited retinal disease treatments."]
Competitors & peers
- Spark Therapeutics (SRPT)
- Luxturna (gene therapy for RPE65-mediated inherited retinal disease, approved; parent company vying for expanded use)
- Biogen (BIIB)
- Novartis (NVS)
- Roche / Genentech
- Janssen Pharmaceuticals
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.